Analysis

Pharmaceutical R&D powered by Global Business Services

Re-Imagining operational R&D through GBS

With the average cost to develop a new drug rapidly increasing, there is a significant opportunity for pharmaceutical organisations to leverage Global Business Services (GBS) to act as a strategic transformation asset.

This document highlights key areas of opportunity across the R&D organisation that could be delivered from a GBS model. Additionally, the report highlights key considerations for leaders to keep in mind as they embark on this journey -

  • Hyper-focus on patient experience
  • Drive innovation through focused partnership models
  • Leverage the scale of GBS and harness its global talent pool
Did you find this useful?
2022 Global Life Sciences Outlook

Digitalization at scale: Delivering on the promise of science

Welcome to the center office

Shifting from a “back-office” to a “center-office” model can enable adaptable and resilient enterprises of the future.